NVS News and Press, Novartis AG

2026-02-27 02:54:16 ET Shares of antisense therapy concern Ionis Pharmaceuticals, Inc. ( IONS ) have rallied strongly since its familial chylomicronemia syndrome med Tryngolza (olezarsen) bore strong data treating severe hypertriglyceridemia. Announced in September 2025, the res...

2026-02-26 14:07:37 ET Shares of cardiopulmonary concern Tenax Therapeutics, Inc. ( TENX ) have roughly doubled since providing a corporate update and presenting with key opinion leaders on November 13, 2025. The company addressed its rationale for advancing oral levosimendan (T...

2026-02-26 13:35:52 ET More on leading drugmakers Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Merck: Why Investors Should Remain Bullish Despite Patent Risks ...

2026-02-25 10:03:10 ET Shares of skin disease concern Oruka Therapeutics, Inc. ( ORKA ) have more than doubled since its IL-23p19 antagonist ORKA-001 demonstrated a half-life four times greater than Skyrizi in a Phase 1 study. The once or twice-yearly psoriasis candidate is undergoi...

2026-02-25 08:31:51 ET More on Novartis Novartis: Value Price, Growth Pipeline Novartis AG 2025 Q4 - Results - Earnings Call Presentation Novartis AG (NVS) Q4 2025 Earnings Call Transcript Trump says tariffs prompt Novartis to expand U.S. manufacturing ...

2026-02-24 16:52:00 ET Many people aim to save at least $1 million for their retirement years to help supplement programs like Social Security. Whether this amount is enough or not, it's certainly much better than nothing. But how should the average person go about saving that type of money...

2026-02-22 15:07:00 ET Novartis (NYSE: NVS) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are extensive, spanning oncology, immunology, neuroscience, respiratory care, and cardiovascular, renal, and metabolic diseases. With a strong...

2026-02-20 15:21:00 ET More on pharmaceutical companies Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects Pfizer: Recovery Isn't Over, Battered Valuation St...

2026-02-20 06:50:50 ET Read the full article on Seeking Alpha For further details see: Trump says tariffs prompt Novartis to expand U.S. manufacturing

2026-02-20 01:34:29 ET More on Novartis Novartis: Value Price, Growth Pipeline Novartis AG 2025 Q4 - Results - Earnings Call Presentation Novartis AG (NVS) Q4 2025 Earnings Call Transcript Novartis inks licensing deal worth up to $1.8B for oral peptide drugs ...